AACR 2023 – Hippo makes a splash
Vivace Therapeutics clinically validates a new mechanism, though its rival Ikena reckons more specificity is needed to avoid toxicity.
Kinnate is the latest Raf player to trip up
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
A surprise Keytruda approval, and what it means for biotech
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
A turn-up for Spectrum’s book
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
